| Â |
Adjuvant
|
Number of Responders (of 5 immunized mice)
|
|---|
N° Doses
|
HBsAg
|
CT
|
CpG
|
Post-prime
|
Post-boost 1
|
Post-boost 2
|
Post-challenge
|
|---|
1 | 1 | Â | Â | 0 | N/Db | N/D | 0 |
1 | 1 | 1 | Â | 0 | N/D | N/D | 3 |
1 | 1 | Â | 1 | 0 | N/D | N/D | 1 |
1 | 1 | 1 | 1 | 0 | N/D | N/D | 4 |
3 | 1 | Â | Â | 0 | 0 | 0 | 0 |
3 | 1 | 1 | Â | 0 | 0 | 0 | 5 |
3 | 1 | Â | 1 | 0 | 0 | 1 | 3 |
3 | 1 | 1 | 1 | 0 | 0 | 2 | 5 |
3 | 1 | 10 | Â | 1 | 2 | 4 | N/D |
3 | 1 | Â | 10 | 0 | 3 | 5 | N/D |
3 | 1 | Â | 50 | 0 | 1 | 3 | N/D |
3 | 1 | 1 | 10 | 1 | 4 | 5 | N/D |
3 | 10 | 1 | Â | 5 | 5 | 5 | N/D |
3 | 10 | 10 | Â | 3 | 4 | 5 | N/D |
3 | 10 | Â | 1 | 3 | 5 | 5 | N/D |
3 | 10 | Â | 10 | 2 | 5 | 5 | N/D |
3 | 10 | Â | 50 | 2 | 5 | 5 | N/D |
3 | 10 | 1 | 1 | 5 | 5 | 5 | N/D |
3 | 10 | 1 | 10 | 5 | 5 | 5 | N/D |
- aBALB/c mice were immunized by intranasal (IN) inhalation of 1 or 10 µg of purified hepatitis B surface antigen (HBsAg) alone (none) or with 1, 10 or 50 µg cholera toxin (CT) and/or CpG-containing oligodeoxynucleotides (CpG) in a total volume of 20 µl. Some mice were boosted in an identical manner at 4 and 8 weeks. Other mice that failed to develop anti-HBs, such as those immunized with 1 µg HBsAg alone or with low dose adjuvant (1 µg), were challenged by intramuscular (IM) injection of 1 µg HBsAg without adjuvant, to determine if immune response had been primed. HBsAg-specific antibody titers were determined by ELISA in plasma taken 4 weeks after final immunization or 2 weeks after challenge. Titers were defined as the highest plasma dilution resulting in an absorbance value two times that of nonimmune plasma, with a cut-off value of 0.05. Values shown represent the number of responding mice (titers > 100).
- bN/D, not determined
